Switch to:
More From Other Websites
AbbVie Nixes Halozyme Drug Partnership (HALO, ABBV) Nov 22 2016
Abbvie Ends Development Program With Halozyme Nov 21 2016
Halozyme Provides Update On AbbVie Collaboration Nov 21 2016
HALOZYME THERAPEUTICS INC Financials Nov 17 2016
ETFs with exposure to Halozyme Therapeutics, Inc. : November 16, 2016 Nov 16 2016
Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016 Nov 15 2016
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US :... Nov 11 2016
Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To... Nov 10 2016
Halozyme 3Q Loss $29M, or 23 Cents a Share (HALO) Nov 09 2016
Edited Transcript of HALO earnings conference call or presentation 7-Nov-16 9:30pm GMT Nov 08 2016
Halozyme Therapeutics reports 3Q loss Nov 07 2016
Halozyme Therapeutics reports 3Q loss Nov 07 2016
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 07 2016
Halozyme Reports Third Quarter 2016 Financial Results Nov 07 2016
Halozyme Reports Third Quarter 2016 Financial Results Nov 07 2016
Q3 2016 Halozyme Therapeutics Inc Earnings Release - After Market Close Nov 07 2016
Coverage initiated on Halozyme Therapeutics by Deutsche Bank Nov 03 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab Nov 03 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK